Mild side effects, such as feeling tired or nauseated, typically subside as the dose equilibrates
When looking at the public overall, 12% of all adults report ever taking these drugs at least in part to treat a chronic condition, including 7% of the public who say they took them primarily to treat a chronic condition and 6% who say they took these drugs to both treat a chronic condition and to lose weight
Theoretical benefits of GLP-1 receptor agonists in Crohn's disease patients center on their anti-inflammatory properties observed in preclinical models
Interaction of tritiated 3 H-25HC with integrins 3 H-25HC was purchased from PerkinElmer (Massachusetts, USA)
The faster onset with IV reflects near-complete bioavailability versus the 2535% absorption rate of even high-quality oral formulations
The shared biological properties of exendin-4 and human GLP-1 probably stem from their primary and secondary structures, but exendin-4 is naturally resistant to degradation by the DPP-4 enzyme, attributed to the presence of glycine at position 2, resulting in an intravenous half-life of approximately 30 minutes (85)